Philip Kam-Tao Li, FRCP; Kai-Ming Chow, MBChB, MRCP(UK); Teresa Yuk-Hwa Wong, MBChB, MRCP(UK); Chi-Bon Leung, MBChB, MRCP(UK); Cheuk-Chun Szeto, MD, MRCP(UK)
The preliminary results of this study were presented at the 35th Annual Meeting of the American Society of Nephrology, 30 October–4 November 2002, Philadelphia, Pennsylvania.
Acknowledgment: The authors thank Ms. Wendy Tang for her clerical assistance and the nursing staff of Renal Unit, Prince of Wales Hospital, Shatin, Hong Kong, for their help in data collection.
Grant Support: In part by research accounts 6901031 and 6900570 from the Chinese University of Hong Kong and in part by Aventis Pharmaceuticals Limited.
Potential Financial Conflicts of Interest: None disclosed.
Requests for Single Reprints: Philip K.-T. Li, FRCP, Department of Medicine and Therapeutics, Prince of Wales Hospital, The Chinese University of Hong Kong, Shatin, Hong Kong; e-mail, email@example.com.
Current Author Addresses: Drs. Li, Chow, Wong, Leung, and Szeto: Department of Medicine and Therapeutics, Prince of Wales Hospital, The Chinese University of Hong Kong, Ngan Shing Street, Shatin, Hong Kong, China.
Author Contributions: Conception and design: P.K.-T. Li.
Analysis and interpretation of the data: K.-M. Chow, C.-B. Leung, C.-C. Szeto.
Drafting of the article: C.-C. Szeto.
Critical revision of the article for important intellectual content: P.K.-T. Li.
Final approval of the article: P.K.-T. Li, T. Y.-H. Wong.
Provision of study materials or patients: P.K.-T. Li.
Statistical expertise: C.-C. Szeto.
Obtaining of funding: P.K.-T. Li.
Administrative, technical, or logistic support: P.K.-T. Li.
Collection and assembly of data: K.-M. Chow, T. Y.-H. Wong, C.-B. Leung, C.-C. Szeto.
Li P., Chow K., Wong T., Leung C., Szeto C.; Effects of an Angiotensin-Converting Enzyme Inhibitor on Residual Renal Function in Patients Receiving Peritoneal Dialysis: A Randomized, Controlled Study. Ann Intern Med. 2003;139:105-112. doi: 10.7326/0003-4819-139-2-200307150-00010
Download citation file:
Published: Ann Intern Med. 2003;139(2):105-112.
Residual renal function is an important determinant of mortality and morbidity in patients receiving peritoneal dialysis (1, 2). It contributes to measures of dialysis adequacy, including Kt/V (dialyzer clearance multiplied by time over volume) and creatinine clearance (3, 4), and accounts for most of the variability in dialysis requirement (5). Previous studies of patients receiving peritoneal dialysis showed that nutritional indices gradually deteriorate when residual renal function declines (2, 6). More important, the ADEMEX (Adequacy of Peritoneal Dialysis in Mexico) study, a recently published randomized, controlled trial, found that increases in doses of fluid for peritoneal dialysis had no effect on patient survival (7). Available data suggest that renal and peritoneal clearances are not equivalent (2, 8, 9) and that an increase in the exchange volume or frequency of peritoneal dialysis cannot completely compensate for loss of residual renal function. As a result, measures to preserve residual renal function are an important target in the treatment of patients receiving dialysis.
to gain full access to the content and tools.
Learn more about subscription options.
Register Now for a free account.
Cardiology, Nephrology, Hypertension, Renal Replacement Therapy, Coronary Risk Factors.
Results provided by:
Copyright © 2016 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use
This PDF is available to Subscribers Only